Mikofenolsav Tillomed (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Mikofenolsav Tillomed, is an antimetabolite immunosuppressant presented as an oral formulation for systemic use. It is used to prevent organ transplant rejection and to treat lupus nephritis in appropriate patients.

GNH USA supplies Mikofenolsav Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolic Acid is employed in immunosuppressive therapy to control immune‑mediated processes.

- Organ transplant rejection: helps prevent graft rejection by suppressing lymphocyte proliferation. - Lupus nephritis: reduces renal inflammation in systemic lupus erythematosus. - Kidney transplant: supports long‑term graft survival by inhibiting T‑ and B‑cell activation.

Mycophenolic Acid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea. - Hematologic changes: anemia, leukopenia, thrombocytopenia. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Headache or dizziness.

Serious or Rare Side Effects: - Severe neutropenia or agranulocytosis. - Opportunistic infections such as Pneumocystis jirovecii pneumonia. - Hepatotoxicity: elevated liver enzymes or hepatitis.

Patients should be monitored regularly for safety and efficacy.

- Monitor blood counts: perform complete blood count before therapy and periodically thereafter. - Assess renal function: adjust therapy if creatinine clearance declines. - Screen for infections: evaluate for active viral or bacterial infections prior to initiation. - Avoid live vaccines: immunosuppression may reduce vaccine efficacy and increase risk. - Pregnancy and lactation: discuss risks with a healthcare professional before use. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Mycophenolic Acid can interact with several drug classes, altering its exposure or increasing toxicity.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of mycophenolic acid. - Azathioprine: additive bone‑marrow suppression. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly decrease drug levels.

Moderate Interactions (Monitor Closely): - Antifungal azoles (ketoconazole, fluconazole): may increase mycophenolic acid concentrations. - ACE inhibitors or ARBs: combined use may worsen renal function. - Vaccines: live attenuated vaccines should be avoided during therapy.